Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 193-206

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antipsychotic; Aripiprazole; Bipolar disorder; Cariprazine; Dosing; Efficacy; Major depressive disorder; Metabolism; Pharmacodynamics; Pharmacokinetics; Safety; Schizophrenia; Tolerability

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARIPRAZINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ILOPERIDONE; LITHIUM; LURASIDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CHEMISTRY; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; HUMAN; INSOMNIA; MAJOR DEPRESSION; MANIA; MIXED MANIA AND DEPRESSION; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERAZINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84872473680     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.759211     Document Type: Review

References (49)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th edition. Text Revision American Psychiatric Publishing, Inc; Arlington, Virginia; 2000
2. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 20091012191728
3. Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12(17):2751-8
4. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122(4):39-48
5. Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D(3)-receptorpreferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 2012; [Epub ahead of print]
6. Agai-Csongor E, Domány G, Nógrádi K, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett 2012;22(10):3437-40
7. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 2011;668(3):355-65
8. Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 2011;59(6):925-35
9. Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl) 2011;218(3):579-87
10. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol 2011;7(7):829-46
11. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011;216(4):451-73
12. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36(2):375-89
13. Sumegi A, Varga E. The dopamin D3 receptor-the gray eminence of pharmacotherapy? Neuropsychopharmacol Hung 2010;12(3):405-11
14. Grunder G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010;11(7):823-32
15. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010;11(7):802-12
16. Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference-Forest Laboratories and Icagen. IDrugs 2010;13(3):145-8
17. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D (3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010;333(1):328-40
18. Deák K, Takács-Novák K, Kapás M, et al. Physico-chemical characterization of a novel group of dopamine D(3)/D(2) receptor ligands, potential atypical antipsychotic agents. J Pharm Biomed Anal 2008;48(3):678-84
19. Mészáros GP, Agai-Csongor E, Kapás M, Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-cariprazine in human plasma and urine. J Pharm Biomed Anal 2008;48(2):388-97
20. Ereshefsky L, Gage A, Yu B, et al. Phase I study of RGH-188 in schizophrenic patients. Poster Presentation NR4-61, American Psychiatric Association 161st Annual Meeting; 3 - 8 May 2008; Washington, DC . Poster describing the Phase I pharmacokinetic study that enrolled subjects with schizophrenia.
21. Litman R, Papadakis K, Durgam S, Xie J. Use of cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Poster Presentation 61, 60th Institute on Psychiatric Services of the American Psychiatric Association; 2 - 5 October 2008; Chicago, Illinois\
22. Bose A, Li D, Migliore R, et al. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Poster Presentation I-73, NCDEU 50th Annual Meeting; 14 - 17 June 2010; Boca Raton, Florida \
23. Cutler A, Bose A, Durgam S, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Poster Presentation NR6-50, American Psychiatric Association 165th Annual Meeting; 5 - 9 May 2012; Philadelphia, Pennsylvania \
24. Knesevich MA, Papadakis K, Bose A, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar disorder: a phase II trial. Poster Presentation NR1-49, American Psychiatric Association 162nd Annual Meeting; 16 - 21 May 2009; San Francisco, California
25. Starace A, Bose A, Wang Q, et al. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, phase III trial. Poster Presentation NR9-42 American Psychiatric Association 165th Annual Meeting; 5 - 9 May 2012; Philadelphia, Pennsylvania . Poster describing a Phase III pivotal trial.
26. Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce positive phase III results with the investigational antipsychotic cariprazine in patients with acute mania associated with bipolar I disorder. Press Release. 8 February 2012 Available from: http://news.frx.com/press- release/productnews/forest-laboratories-inc-and-gedeonrichter-plc-announce- positive-phase-ii [Last accessed 06 November 2012]
27. Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce results from a phase II study of cariprazine for the treatment of bipolar depression. Press Release. 30 August 2010 Available from: http://news.frx.com/press-release/rd-news/forestlaboratories-inc-and-gedeon- richter-plcannounce-results-phase-ii-stu-0 [Last accessed 06 November 2012]
28. Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce results from a phase II study of cariprazine as adjunctive therapy in major depressive disorder. Press Release. 28 February 2011 Available from: http://news.frx.com/press-release/rd-news/forest-laboratories-inc-andgedeon- richter-plc-announce-resultsphase-ii-study [Last accessed 06 November 2012]
29. Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc Announce results from two positive phase III trials with the investigational antipsychotic cariprazine for the treatment of schizophrenia. Press Release. 28 February 2012 Available from: http://news.frx.com/press-release/rd-news/ forestlaboratories-inc-and-gedeon-richter-plcannounce-results-two-positive-p [Last accessed 06 November 2012]
30. Csongor C, Galambos J, Nogradi K, et al. Pub. No.: US20060229297A1. 12 October 2006 Available from: http://www.google.com/patents/US20060229297 [[Last accessed 1 November 2012]
31. Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf 2011;10(3):437-48
32. Citrome L. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. CNS Spectr 2012;17(Suppl 1):1-9
33. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(10 Suppl 11):6-14 (Pubitemid 39473434)
34. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006;2(4):427-43 (Pubitemid 46321873)
35. Otsuka Pharmaceutical Co. Abilify (aripiprazole). Revised February 2012 Available from: http://www.abilify.com/pdf/pi.aspx [Last accessed 12 November 2012]
36. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(5):617-24
37. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012;25(2):96-102
38. Auclair AL, Cathala A, Sarrazin F, et al. The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 2010;114(5):1323-32
39. Laszlovsky I, Nemeth G, Meszaros GP, et al. Dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers. Eur Neuropsychopharmacol 2007;17(Suppl 4):S455
40. Keator DB, Mukherjee J, Preda A, et al. Dopamine D2 and. D3 receptor occupancy of cariprazine in schizophrenic patients. Schizophr Bull 2009;35(Suppl 1):154
41. Potkin S, Keator D, Mukherjee J, et al. Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol 2009;19(Suppl 3):S316
42. Meszaros GP, Kapas M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol 2007;217(Suppl 4):S451-2
43. Kapas M, Meszaros GP, Yu B, et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. Eur Neuropsychopharmacol 2008;18(Suppl 4):433
44. Kirschner N, Gemesi LI, Vastag M, et al. In vitro metabolism of RGH-188. Drug Metab Rev 2008;40(Suppl 1):128-9
45. Forest Laboratories, Inc. Forest laboratories submits new drug application for cariprazine for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar I disorder. Press Release. 28 November 2012 Available from: http://news.frx. com/press-release/corporate-news/ forestlaboratories-submits-new-drugapplication-cariprazine-treatment- [Last accessed 10 December 2012]
46. Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5(1):23-43
47. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27 (Pubitemid 29189265)
48. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320(1):1-13 (Pubitemid 46025713)
49. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 201064670718